Tenecteplase drug is a recombinant enzyme used as a blood thinning agent. It is also called as clot buster, it dissolves the blood clots or clumps so that the blood could flow normally. Tenecteplase drug is mostly used to treat patients having heart-related diseases. Key factors, that favors the growth of this market are an increase in the rate of hypertension patient, increasing number of deep vein thrombosis cases, early aging and sitting for long period of time cause blood clotting. According to the American Heart Association 2017 report every 40 seconds, someone in the U.S has a heart attack. American College of Cardiology 2018 report states the death rate related to high blood pressure (BP) from 2005- 2015, has increased by 10.5%.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6401

Further, the report presented statistics like- Coronary heart disease (CHD) (43.8%) is the major cause of deaths attributable to cardiovascular disease (CVD) in the US, followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). Further, they projected by 2035, more than 130 million adults in the US population (45.1%) to have some form of CVD. The total costs of CVD are expected to reach USD 1.1 trillion in 2035. Stroke prevalence in adults is 2.7% in the United States. Similarly, as per CDC’s facts and statistics about stroke in the United States report 2017, every 140,000 Americans die every year due to stroke. Thus, the increasing rate of cardiovascular diseases increases the market growth of tenecteplase drug market in this region.

Key players

Some of the key players in the global tenecteplase drug market companies are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.


The global tenecteplase drug market is segmented on the basis of application, dosage and end users.

The tenecteplase drug market, by application segmented into myocardial infarction, stroke, deep vein thrombosis. The tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the bases of end-user, it is segmented into hospitals and clinics, surgical centers, research centers and other.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/tenecteplase-drug-market-6401